A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs AMG 557 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jul 2012 Planned End Date changed from 1 Dec 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 06 Mar 2012 Additional lead trial investigator identified as reported by Oregon Health and Science University Institutional Review Board.
    • 06 Mar 2012 New source identified and integrated (IRB00007784; Oregon Health and Science University Institutional Review Board).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top